Blood-Based MRD Testing Correlates With Bone Marrow Testing in Multiple Myeloma -EasyM | IMS 2026

Abir Khaled, a senior scientist at EasyM, discusses a blood-based test for minimal residual disease (MRD) at IMS 2026 in Glasgow. MRD testing usually requires a bone marrow biopsy. She shares an update on an ongoing Canadian multicenter study following 70 patients to compare the mass spectrometry blood test with standard bone marrow testing. Early results suggest the two correlate well, and a less invasive option could make MRD monitoring easier for patients.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.